New advances in the study of subthreshold micropulse laser photocoagulation for central serous chorioretinopathy
10.3760/cma.j.cn511434-20230306-00108
- VernacularTitle:阈值下微脉冲激光治疗中心性浆液性脉络膜视网膜病变的研究新进展
- Author:
Yuan QI
1
;
Liya LIU
;
Feiyan MA
;
Qingli SHANG
Author Information
1. 河北医科大学第二医院眼科, 石家庄 050000
- Keywords:
Central serous chorioretinopathy;
Laser coagulation;
Subthreshold micropulse laser;
Review
- From:
Chinese Journal of Ocular Fundus Diseases
2023;39(4):337-340
- CountryChina
- Language:Chinese
-
Abstract:
Central serous chorioretinopathy (CSC) is a common macular disease, which can lead to the loss of central vision in young patients. Although the disease is self-limited to some extent, there is no shortage of patients with prolonged course and recurrent attacks, eventually leading to irreversible visual impairment. Therefore, taking reasonable treatment in a certain period is particularly important for the visual prognosis of patients. Although thermal laser photocoagulation of leakage points and photodynamic therapy (PDT) have achieved good effects, there are risks of retinal damage and retinal pigment epithelium atrophy. Subthreshold micropulse laser (SMLP) is a kind of subthreshold short pulse laser, which does not cause visible damage to the retina and is safer. In the era of lack of PDT drugs, SMLP has gradually become an important means of clinical treatment for CSC, especially for patients with no obvious leakage point or subfoveal leakage point. An in-depth understanding of the mechanism of action of SMLP and its efficacy and safety in the treatment of CSC is helpful for the promotion and application of SMLP in the clinical treatment of CSC.
